Little's Colchicine may be available in the countries listed below.
Colchicine is reported as an ingredient of Little's Colchicine in the following countries:
International Drug Name Search
Pamba may be available in the countries listed below.
Aminomethylbenzoic Acid is reported as an ingredient of Pamba in the following countries:
International Drug Name Search
Tegrital may be available in the countries listed below.
Carbamazepine is reported as an ingredient of Tegrital in the following countries:
International Drug Name Search
Prindace may be available in the countries listed below.
Perindopril is reported as an ingredient of Prindace in the following countries:
International Drug Name Search
Metronidazol B. Braun may be available in the countries listed below.
Metronidazole is reported as an ingredient of Metronidazol B. Braun in the following countries:
International Drug Name Search
Demotick may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Amitraz is reported as an ingredient of Demotick in the following countries:
International Drug Name Search
Decafos may be available in the countries listed below.
Dexamethasone 21-(disodium phosphate) (a derivative of Dexamethasone) is reported as an ingredient of Decafos in the following countries:
International Drug Name Search
Sedoxil may be available in the countries listed below.
Mexazolam is reported as an ingredient of Sedoxil in the following countries:
International Drug Name Search
Ben-Gay may be available in the countries listed below.
Salicylic Acid is reported as an ingredient of Ben-Gay in the following countries:
International Drug Name Search
Pantelmin may be available in the countries listed below.
Mebendazole is reported as an ingredient of Pantelmin in the following countries:
International Drug Name Search
Lipirex may be available in the countries listed below.
Fenofibrate is reported as an ingredient of Lipirex in the following countries:
International Drug Name Search
Ondran may be available in the countries listed below.
Ondansetron hydrochloride (a derivative of Ondansetron) is reported as an ingredient of Ondran in the following countries:
International Drug Name Search
Amiklin pédiatrique may be available in the countries listed below.
Amikacin sulfate (a derivative of Amikacin) is reported as an ingredient of Amiklin pédiatrique in the following countries:
International Drug Name Search
In the US, Nesacaine (chloroprocaine systemic) is a member of the drug class local injectable anesthetics and is used to treat Local Anesthesia.
US matches:
Chloroprocaine hydrochloride (a derivative of Chloroprocaine) is reported as an ingredient of Nesacaine in the following countries:
International Drug Name Search
Gabapentin Arcana may be available in the countries listed below.
Gabapentin is reported as an ingredient of Gabapentin Arcana in the following countries:
International Drug Name Search
Alfacip may be available in the countries listed below.
Alfacalcidol is reported as an ingredient of Alfacip in the following countries:
International Drug Name Search
Doctamoxifene may be available in the countries listed below.
Tamoxifen is reported as an ingredient of Doctamoxifene in the following countries:
International Drug Name Search
Mogadon may be available in the countries listed below.
Nitrazepam is reported as an ingredient of Mogadon in the following countries:
International Drug Name Search
Gaveril may be available in the countries listed below.
Buflomedil hydrochloride (a derivative of Buflomedil) is reported as an ingredient of Gaveril in the following countries:
International Drug Name Search
Digoxina may be available in the countries listed below.
Digoxin is reported as an ingredient of Digoxina in the following countries:
International Drug Name Search
In the US, Genasyme (simethicone systemic) is a member of the drug class miscellaneous GI agents and is used to treat Endoscopy or Radiology Premedication, Functional Gastric Disorder, Gas and Postoperative Gas Pains.
US matches:
Simeticone is reported as an ingredient of Genasyme in the following countries:
International Drug Name Search
Uphalexin may be available in the countries listed below.
Cefalexin is reported as an ingredient of Uphalexin in the following countries:
International Drug Name Search
Glimepiride OGB Dexa may be available in the countries listed below.
Glimepiride is reported as an ingredient of Glimepiride OGB Dexa in the following countries:
International Drug Name Search
Cypron may be available in the countries listed below.
Cyproterone 17α-acetate (a derivative of Cyproterone) is reported as an ingredient of Cypron in the following countries:
International Drug Name Search
Cisplatin Hospira may be available in the countries listed below.
Cisplatin is reported as an ingredient of Cisplatin Hospira in the following countries:
International Drug Name Search
In the US, Taxol (paclitaxel systemic) is a member of the drug class mitotic inhibitors and is used to treat Breast Cancer, Breast Cancer - Adjuvant, Breast Cancer - Metastatic, Kaposi's Sarcoma, Non-Small Cell Lung Cancer, Ovarian Cancer and Wilms' Tumor.
US matches:
Paclitaxel is reported as an ingredient of Taxol in the following countries:
International Drug Name Search
Cetirizin Streuli may be available in the countries listed below.
Cetirizine dihydrochloride (a derivative of Cetirizine) is reported as an ingredient of Cetirizin Streuli in the following countries:
International Drug Name Search
Ondansetron Merck may be available in the countries listed below.
Ondansetron hydrochloride (a derivative of Ondansetron) is reported as an ingredient of Ondansetron Merck in the following countries:
International Drug Name Search
Prosexol may be available in the countries listed below.
Ethinylestradiol is reported as an ingredient of Prosexol in the following countries:
International Drug Name Search
The following drugs and medications are in some way related to, or used in the treatment of Intra- or Post-op SVT or Hypertension. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
Atimos may be available in the countries listed below.
Formoterol is reported as an ingredient of Atimos in the following countries:
Formoterol fumarate (a derivative of Formoterol) is reported as an ingredient of Atimos in the following countries:
Formoterol fumarate dihydrate (a derivative of Formoterol) is reported as an ingredient of Atimos in the following countries:
International Drug Name Search
Carboprost Tromethamine may be available in the countries listed below.
Carboprost Tromethamine (USAN) is known as Carboprost in the US.
International Drug Name Search
Glossary
| USAN | United States Adopted Name |
Steocalcin may be available in the countries listed below.
Calcitonin is reported as an ingredient of Steocalcin in the following countries:
International Drug Name Search
Levixa may be available in the countries listed below.
Fosamprenavir calcium salt (a derivative of Fosamprenavir) is reported as an ingredient of Levixa in the following countries:
International Drug Name Search
Loxyn may be available in the countries listed below.
Amoxicillin trihydrate (a derivative of Amoxicillin) is reported as an ingredient of Loxyn in the following countries:
International Drug Name Search
Bio-Heparin may be available in the countries listed below.
Heparin sodium salt (a derivative of Heparin) is reported as an ingredient of Bio-Heparin in the following countries:
International Drug Name Search
Nivitron may be available in the countries listed below.
Nitrendipine is reported as an ingredient of Nivitron in the following countries:
International Drug Name Search
Selederm may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Selenium Sulfide is reported as an ingredient of Selederm in the following countries:
International Drug Name Search
Intramin may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Ampicillin trihydrate (a derivative of Ampicillin) is reported as an ingredient of Intramin in the following countries:
International Drug Name Search
Micropaque may be available in the countries listed below.
Barium Sulfate is reported as an ingredient of Micropaque in the following countries:
International Drug Name Search
Insulatard HM FlexPen may be available in the countries listed below.
Insulin, Isophane human (a derivative of Insulin, Isophane) is reported as an ingredient of Insulatard HM FlexPen in the following countries:
International Drug Name Search
Lanser may be available in the countries listed below.
Lansoprazole is reported as an ingredient of Lanser in the following countries:
International Drug Name Search
Aspirin Domesco may be available in the countries listed below.
Acetylsalicylic Acid is reported as an ingredient of Aspirin Domesco in the following countries:
International Drug Name Search
Pindolol Mylan may be available in the countries listed below.
Pindolol is reported as an ingredient of Pindolol Mylan in the following countries:
International Drug Name Search
Insulin Humaject 30/70 may be available in the countries listed below.
Insulin Injection, Biphasic Isophane human (a derivative of Insulin Injection, Biphasic Isophane) is reported as an ingredient of Insulin Humaject 30/70 in the following countries:
International Drug Name Search
Teofilina Biocrom may be available in the countries listed below.
Theophylline is reported as an ingredient of Teofilina Biocrom in the following countries:
International Drug Name Search
Glauteolol may be available in the countries listed below.
Carteolol hydrochloride (a derivative of Carteolol) is reported as an ingredient of Glauteolol in the following countries:
International Drug Name Search
Amisulprid-ratiopharm may be available in the countries listed below.
Amisulpride is reported as an ingredient of Amisulprid-ratiopharm in the following countries:
International Drug Name Search
Adinir may be available in the countries listed below.
Cefdinir is reported as an ingredient of Adinir in the following countries:
International Drug Name Search
Sulfat de Atropinã may be available in the countries listed below.
Atropine sulfate (a derivative of Atropine) is reported as an ingredient of Sulfat de Atropinã in the following countries:
International Drug Name Search
Misostol may be available in the countries listed below.
Mitoxantrone is reported as an ingredient of Misostol in the following countries:
Mitoxantrone dihydrochloride (a derivative of Mitoxantrone) is reported as an ingredient of Misostol in the following countries:
International Drug Name Search
Cyplegin may be available in the countries listed below.
Cyclopentolate hydrochloride (a derivative of Cyclopentolate) is reported as an ingredient of Cyplegin in the following countries:
International Drug Name Search
Gastron may be available in the countries listed below.
Loperamide hydrochloride (a derivative of Loperamide) is reported as an ingredient of Gastron in the following countries:
International Drug Name Search
Enpral may be available in the countries listed below.
Omeprazole is reported as an ingredient of Enpral in the following countries:
International Drug Name Search
Paraclodin may be available in the countries listed below.
Ticlopidine hydrochloride (a derivative of Ticlopidine) is reported as an ingredient of Paraclodin in the following countries:
International Drug Name Search
Pamired may be available in the countries listed below.
Pamidronic Acid disodium salt (a derivative of Pamidronic Acid) is reported as an ingredient of Pamired in the following countries:
International Drug Name Search
Sefalor may be available in the countries listed below.
Cefaclor monohydrate (a derivative of Cefaclor) is reported as an ingredient of Sefalor in the following countries:
International Drug Name Search
Pyrantel Paste may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Pyrantel embonate (a derivative of Pyrantel) is reported as an ingredient of Pyrantel Paste in the following countries:
International Drug Name Search
Tiapaston may be available in the countries listed below.
Tiquizium Bromide is reported as an ingredient of Tiapaston in the following countries:
International Drug Name Search
Doprovet may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Doxycycline monohydrate (a derivative of Doxycycline) is reported as an ingredient of Doprovet in the following countries:
International Drug Name Search
Tozolden may be available in the countries listed below.
Atenolol is reported as an ingredient of Tozolden in the following countries:
International Drug Name Search
Beta Ointment may be available in the countries listed below.
Betamethasone 17α-valerate (a derivative of Betamethasone) is reported as an ingredient of Beta Ointment in the following countries:
International Drug Name Search
Cystichol may be available in the countries listed below.
Choline hydrogentartrate (a derivative of Choline) is reported as an ingredient of Cystichol in the following countries:
Cystine is reported as an ingredient of Cystichol in the following countries:
International Drug Name Search
Oxytocin Bengen may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Oxytocin is reported as an ingredient of Oxytocin Bengen in the following countries:
International Drug Name Search
Genta-Sulfat may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Gentamicin sulfate (a derivative of Gentamicin) is reported as an ingredient of Genta-Sulfat in the following countries:
International Drug Name Search
Novo-Gesic may be available in the countries listed below.
Paracetamol is reported as an ingredient of Novo-Gesic in the following countries:
International Drug Name Search
Treating mild to moderate itching, redness, and swelling caused by certain skin conditions.
DesOwen Cream is a topical corticosteroid. It works by reducing skin inflammation (redness, swelling, itching, and irritation).
Contact your doctor or health care provider right away if any of these apply to you.
Some medical conditions may interact with DesOwen Cream. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:
Some MEDICINES MAY INTERACT with DesOwen Cream. Because little, if any, of DesOwen Cream is absorbed into the blood, the risk of it interacting with another medicine is low.
Ask your health care provider if DesOwen Cream may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.
Use DesOwen Cream as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Ask your health care provider any questions you may have about how to use DesOwen Cream.
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:
Mild, temporary stinging or burning when first applied.
Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); acne-like rash; inflamed hair follicles; inflammation around the mouth; severe or persistent burning, irritation, redness, or swelling of the skin; thinning, softening, or discoloration of the skin.
This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.
See also: DesOwen side effects (in more detail)
Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include blurred vision or other vision changes; muscle weakness; severe or persistent headache; symptoms of high blood sugar (eg, increased thirst or urination, confusion, unusual drowsiness); unusual weight gain, especially in the face.
Store DesOwen Cream at room temperature, between 59 and 86 degrees F (15 and 30 degrees C). Store in a tightly closed container. Do not freeze. Store away from heat, moisture, and light. Do not store in the bathroom. Keep DesOwen Cream out of the reach of children and away from pets.
This information is a summary only. It does not contain all information about DesOwen Cream. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.
The following drugs and medications are in some way related to, or used in the treatment of Non-Small Cell Lung Cancer. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
Micromedex Care Notes:
Harvard Health Guide:
Class: Androgens
ATC Class: A14AA
VA Class: HS100
Chemical Name: 17β-Hydroxy-17-αmethyl-2-oxa-5α-androstan-3-one
Molecular Formula: C19H30O3
CAS Number: 53-39-4
Brands: Oxandrin
Peliosis hepatis, a condition in which the liver contains blood-filled cysts, reported with androgen therapy.1 4 30 31 34 May present with minimal hepatic dysfunction,1 4 34 or effects may not be apparent until complicated by life-threatening liver failure or rupture of the cysts resulting in intra-abdominal hemorrhage.1 4 5 7 31 34 (See Hepatic Effects under Cautions.)
Discontinuance of androgen therapy usually results in resolution of liver lesions.1 4 32 34
Liver cell tumors reported with androgen therapy.1 4 5 7 30 31 34 Tumors are usually benign and androgen dependent; hepatocellular carcinoma, sometimes fatal, also reported.1 4 5 7 34
Liver cell tumors associated with androgens are more vascular than other hepatic tumors; hepatic effects may not be apparent until complicated by life-threatening intra-abdominal hemorrhage.1 4 5 34
Discontinuance of androgen therapy often but not always results in regression or cessation of progression of the tumor.1 4 5 34
May markedly alter serum lipoprotein concentrations; decreased HDL- and increased LDL-cholesterol reported with androgen therapy.1 4 30 31 34 Consider increased risk of cardiovascular disease (e.g., atherosclerosis and CAD).1 4 31 34 (See Lipid Abnormalities under Cautions.)
Synthetic androgenic anabolic steroid hormone.1 4
Adjunct to conventional therapy to promote weight gain in individuals who experience weight loss following extensive surgery, chronic infections (e.g., HIV-associated wasting syndrome; designated an orphan drug by FDA for this use),3 or severe trauma (e.g., burns, spinal cord injury).1 5 17 19 22 32
Adjunct to conventional therapy for management of unexplained weight loss.1
Adjunct to conventional therapy to offset protein catabolism (e.g., muscle wasting, muscle pain or weakness, delayed wound healing, atrophy of protein matrix of bone) associated with long-term corticosteroid therapy.1 4 20 21 33
Labeled for the symptomatic treatment of bone pain accompanying osteoporosis.1 4 23
Androgens have been misused and abused by athletes, bodybuilders, weight lifters, and others to enhance athletic performance or physique†.6 7 8 9 10 32
Medical and sports experts (e.g., International Olympic Committee) consider such use to be inappropriate and unacceptable because of known adverse effects and potential long-term sequelae.9 Such misuse by athletes is contrary to rules and ethical principles of athletic competition.7 8 9 10
Manufacturer states that androgens have not been shown to enhance athletic performance.1
Individualize dosage and duration of therapy carefully according to individual requirements, response, and tolerance.1 4 Use the minimum effective dosage; intended for intermittent use.1 4 22
Administer orally 2–4 times daily in adults.1 4
≤0.1 mg/kg daily for 2–4 weeks.1 4 Repeat course of therapy intermittently as needed to maintain weight.1 4 32
Manufacturer states that a 2- to 4-week course of therapy usually is adequate to observe a response (i.e., slowing or cessation of weight loss).1 4 32 A longer period of treatment is necessary to regain lost weight, especially if ongoing catabolic stressors are present.32
Higher than recommended dosage of 0.1 mg/kg twice daily for 5 days to 12 months† has been evaluated in pediatric patients with burns.1 4 5 16 17 18 32
≤0.1 mg/kg daily.1 4 Manufacturer states that a 2- to 4-week course of therapy usually is adequate to observe a response.1 4 32 Repeat course of therapy intermittently as needed.1 4 32
2.5–20 mg daily in 2–4 divided doses for 2–4 weeks.1 4 Repeat course of therapy intermittently as needed to maintain weight.1 4 32
Manufacturer states that a 2- to 4-week course of therapy usually is adequate to observe a response (i.e., slowing or cessation of weight loss).1 4 32 A longer period of treatment is necessary to regain lost weight, especially if ongoing catabolic stressors are present.32 Continuous administration for 3–4 months has been evaluated in patients with HIV-associated wasting syndrome.5 19
2.5–20 mg daily in 2–4 divided doses.1 4 Manufacturer states that a 2- to 4-week course of therapy usually is adequate to observe a response.1 4 32 Repeat course of therapy intermittently as needed.1 4 32
2.5–20 mg daily in 2–4 divided doses.1 4 Manufacturer states that a 2- to 4-week course of therapy usually is adequate to observe a response.1 4 Repeat course of therapy intermittently as needed.1 4
5 mg twice daily for 2–4 weeks recommended.1 Repeat course of therapy intermittently as needed.1 (See Geriatric Use under Cautions.)
Males with breast cancer or known or suspected prostate cancer.1 4
Women with hypercalcemia associated with metastatic breast cancer.1 4 (See Hypercalcemia under Cautions.)
Known or suspected pregnancy.1 4 (See Fetal/Neonatal Morbidity and Mortality under Cautions.)
Nephrosis.1 4
Hypercalcemia.1 4 (See Hypercalcemia under Cautions.)
May cause fetal harm; potential for virilization of fetus.1 4
Fetotoxicity, embryotoxicity, infertility, and virilization of female offspring demonstrated in animals.1 4
Potentially serious and/or life-threatening adverse hepatic effects (e.g., peliosis hepatis, hepatic adenomas, hepatocellular carcinoma) associated with prolonged use of high dosages of androgens.5 6 7 9 10 22 (See Boxed Warning.)
If cholestatic hepatitis with jaundice occurs, or if liver function test results become abnormal during therapy, discontinue oxandrolone and investigate etiology of these disorders.1 4 Drug-induced jaundice usually is reversible after discontinuance of drug.1 4
Monitor liver function periodically.1 4 17 22
Possible hypercalcemia resulting from osteolysis in women with metastatic carcinoma of the breast.1 4 Monitor urine and serum calcium concentrations frequently during the course of androgen therapy in women with metastatic breast cancer.1 4 30
If hypercalcemia occurs, discontinue the drug.1 4 (See Contraindications under Cautions.)
Edema, with or without CHF, possible as a result of sodium and water retention and may be a serious complication in patients with preexisting cardiac, renal, or hepatic disease.1 4 30 (See Geriatric Use under Cautions.)
Potential for serious adverse effects (e.g., increased aggression,6 7 8 10 13 22 antisocial behavior,6 7 manic episode,6 22 depression,9 changes in libido,6 7 8 9 10 22 increased risk of cardiovascular disease,6 7 8 9 hepatotoxicity6 7 8 9 10 ) associated with misuse and abuse of androgens (see Misuse and Abuse under Uses); oxandrolone preparations currently subject to control under the Federal Controlled Substances Act of 1970, as amended by the Anabolic Steroids Control Act of 1990 and 2004, as schedule III (C-III) drugs.11 32
Virilization, including baldness, clitoral enlargement, deepening of voice, hirsutism, and menstrual irregularities, may occur in females.1 4 5 6 9 13
Monitor women receiving oxandrolone therapy for signs of virilization.1 4 If virilization occurs, promptly discontinue therapy.1 4 Some changes may not be reversible (e.g., clitoral enlargement, voice changes) after discontinuance of the drug; concomitant use of estrogen with androgens does not prevent these effects.1 4 6 7 32
Possible polycythemia, especially with high dosages of androgens.1 4 30 Perform periodic hemoglobin and hematocrit determinations in patients receiving high dosages of androgens.1 4 30
Anabolic steroids may suppress clotting factors II, V, VII, and X and prolong PT.1 4 (See Specific Drugs and Laboratory Tests under Interactions.)
Androgens may increase LDL-cholesterol and decrease HDL-cholesterol concentrations; consider the increased risk for cardiovascular disease.1 4 5 6 7 10 12 13 19 22 32 Lipid concentrations return to baseline values approximately 1 month after discontinuance of androgen therapy.22
Use with caution in patients with cardiovascular disease or risk factors for cardiovascular disease.1 4 Determine serum lipid concentrations periodically; adjust therapy accordingly.1 4
Category X.1 4 (See Fetal/Neonatal Morbidity and Mortality and also Contraindications under Cautions.)
Not known whether oxandrolone is distributed into milk.1 4 Discontinue nursing or the drug.1 4
May accelerate bone maturation without producing compensatory gain in linear growth, possibly resulting in compromised adult stature.1 4 10 The younger the child, the greater the risk of the drug compromising final mature stature.1 4
Use with extreme caution in children and only under the supervision of a specialist who is aware of the adverse effects of oxandrolone on bone maturation.1 4 Perform radiographic examination of the left hand and wrist every 6 months to determine rate of bone maturation and to assess the effect of treatment on epiphyseal centers.1 4
Possible increased risk of developing prostatic hypertrophy and prostate cancer during androgen therapy.1 4 30
Response in patients ≥65 years of age does not appear to differ from that in younger adults.1 Increased sensitivity to fluid retention and increases in hepatic transaminase values reported, particularly in geriatric women.1 Use lower dosage to minimize adverse effects.1 (See Geriatric Patients under Dosage and Administration.)
Elevated aminotransferases (ALT, AST),1 4 5 13 17 19 lipid abnormalities (e.g., decreased HDL cholesterol concentrations).1 4 5 13 19
Drug or Test | Interaction | Comments |
|---|---|---|
Anticoagulants, oral | May potentiate action of oral anticoagulants and decrease anticoagulant requirements1 4 22 24 26 32 Increases AUC and half-life of warfarin; minor bleeding reported;1 4 80-85% decrease in warfarin dosage (from a mean of 6.13 mg daily to a mean of 1.13 mg daily) were needed to maintain target INR of 1.5 in one study1 4 32 | Monitor PT or INR when oxandrolone therapy is initiated or discontinued in patients receiving oral anticoagulants and adjust anticoagulant dosage as needed1 4 32 Initial anticoagulant dosage may be substantially lower in patients receiving oxandrolone32 Monitor for signs and symptoms of occult bleeding1 4 |
Antidiabetic agents, oral (sulfonylureas) | Possible inhibition of sulfonylurea metabolism1 4 32 | Use concomitantly with care6 |
Corticotropin (ACTH) and corticosteroids | May exacerbate edema1 4 | Consider possibility of interaction before use13 |
Tests for thyroid function | Possible decreased thyroxine-binding globulin concentrations, resulting in decreased total serum thyroxine (T4) concentrations and increased resin uptake of triiodothyronine (T3) and T41 4 16 Free thyroid hormone concentrations remain unchanged1 4 May decrease protein-bound iodine (PBI) concentrations and radioactive iodine uptake1 4 |
Well absorbed after oral administration, with peak serum concentrations attained in approximately 1 hour.5 13
95%.5 13
Partially metabolized via sulfation to 17-epioxandrolone; other metabolites also identified.5 13 14 25 27 28
Excreted principally in urine as unchanged and unconjugated oxandrolone (28%).5 25 27
Biphasic; distribution half-life is 30 minutes and elimination half-life is approximately 10.4 hours in adults.1 5 25
In geriatric individuals, elimination half-life is 13.3 hours.1
20–25°C.4
Produces marked anabolic activity and relatively few androgenic effects.5 6 7 13 14 22
Produces retention of nitrogen,5 7 13 17 22 increases protein anabolism and amino acid utilization, and decreases urinary calcium concentrations.2 5 13 16 18 23
Increases lean body mass, body cell mass, and muscle strength.7 9 16 17 18 19 20 22
Increases bone mineral density and content.5 13 16 22
Inhibits protein catabolism induced by corticosteroids.5 6 8 17 22
Androgens stimulate production of erythrocytes, apparently by enhancing production of erythropoietin.22 (See Hematologic Effects under Cautions.)
Inhibits release of endogenous testosterone via feedback inhibition of pituitary luteinizing hormone (LH).1 4 7 8 10 19 22 32
Large doses of androgens may suppress spermatogenesis.1 4 6 7 8 9 22
Risk of virilization in females.1 2 4 6 Advise female patients to contact their clinician if they notice hoarseness, acne, menstrual changes, baldness, genital changes, or growth of facial hair.1 2 4
Risk of priapism; importance of males informing clinicians if too frequent or persistent penile erections occur.1 4
Advise male patients to contact their clinician if they notice new or worsening acne.1 4
Importance of periodic assessments to determine rate of bone maturation in pediatric patients.1 4
Importance of informing clinician if nausea, vomiting, changes in skin color, or ankle swelling occurs.1 4
Risk of potential liver toxicity and/or lipid abnormalities (e.g., increased LDL-cholesterol concentrations and decreased HDL-cholesterol concentrations.1 4 Importance of regular laboratory monitoring of liver function and cholesterol concentrations.1 4
Importance of women informing their clinician if they are or plan to become pregnant or plan to breast-feed.1 4
Importance of informing clinician of existing or contemplated concomitant therapy, including prescription (e.g., warfarin, antidiabetic medications) and OTC drugs and herbal supplements, as well as any concomitant illnesses.1 4
Importance of informing patients of other important precautionary information.1 4 (See Cautions.)
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
Oxandrolone is subject to control under the Federal Controlled Substances Act of 1970, as amended by the Anabolic Steroids Control Act of 1990 and 2004, as a schedule III (C-III) drug.11
Routes | Dosage Forms | Strengths | Brand Names | Manufacturer |
|---|---|---|---|---|
Oral | Tablets | 2.5 mg | Oxandrin ( C-III; scored) | Savient |
Oxandrolone Tablets ( C-III; scored) | ||||
10 mg | Oxandrin ( C-III) | Savient | ||
Oxandrolone Tablets ( C-III) |
This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 03/2011. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.
Oxandrin 10MG Tablets (SAVIENT PHARMACEUTICALS INC.): 30/$822.73 or 60/$1621.34
Oxandrin 2.5MG Tablets (SAVIENT PHARMACEUTICALS INC.): 30/$249.24 or 90/$725.97
Oxandrolone 10MG Tablets (SANDOZ): 30/$535.96 or 90/$1577.85
This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.
The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.
AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions April 2010. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.
† Use is not currently included in the labeling approved by the US Food and Drug Administration.
1. Savient Pharmaceuticals. Oxandrin (oxandrolone) tablets prescribing information. East Brunswick, NJ; 2006 Jan.
2. AHFS consumer medication information. Oxandrolone. Bethesda, MD: American Society of Health-System Pharmacists; 2004 Oct 1. Available from website. Accessed 2008 Mar 7.
3. Food and Drug Administration. List of orphan designations and approvals. Rockville, MD; 2007 Oct 4. From FDA website. Accessed 2008 Mar 7.
4. Par Pharmaceutical Companies. Oxandrolone tablets prescribing information. Spring Valley, NY; 2007 Mar 3.
5. Orr R, Singh MF. The anabolic androgenic steroid oxandrolone in the treatment of wasting and catabolic disorders: review of efficacy and safety. Drugs. 2004; 64:725-50. [PubMed 15025546]
6. Kam PCA, Yarrow M. Anabolic steroid abuse: physiological and anaesthetic considerations. Anaesthesia. 2005; 60:685-92. [PubMed 15960720]
7. American College of Sports Medicine. Position stand on the use of anabolic-androgenic steroids in sports. Med Sci Sports Exerc. 1987; 19:534-9. [PubMed 3316907]
8. Committee on Sports Medicine and Fitness, American Academy of Pediatrics. Adolescents and anabolic steroids: a subject review. Pediatrics. 1997; 99:904-8. [PubMed 9190555]
9. Council on Scientific Affairs, American Medical Association. Medical and nonmedical uses of anabolic-androgenic steroids. JAMA. 1990; 264:2923-7. [IDIS 274793] [PubMed 2232088]
10. Council on Scientific Affairs, American Medical Association. Drug abuse in athletes: anabolic steroids and human growth hormone. JAMA. 1988; 259:1703-5. [IDIS 239600] [PubMed 3278150]
11. Drug Enforcement Administration (DEA), Department of Justice. Implementation of the Anabolic Steroid Control Act of 2004. Final rule. [21 CFR Part 1300 and 1308] Fed Regist. 2005; 70:74653-8.
12. American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists medical practice guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients—2002 update. Endocr Pract. 2002; 8:440-56. [PubMed 15260010]
13. Akyurek M, Dunn RM. Oxandrolone. Plast Reconstr Surg. 2006; 118:791-4. [PubMed 16932191]
14. Schänzer W. Metabolism of anabolic androgenic steroids. Clin Chem. 1996; 42:1001-20.
16. Przkora R, Jeschke MG, Barrow RE et al. Metabolic and hormonal changes in severely burned children receiving long-term oxandrolone treatment. Ann Surg. 2005; 242:384-91. [PubMed 16135924]
17. Jeschke MG, Finnerty CC, Suman OE et al. The effect of oxandrolone on the endocrinologic, inflammatory, and hypermetabolic reponses during the acute phase postburn. Ann Surg. 2007; 246:351-62. [PubMed 17717439]
18. Wolf SE, Thomas SJ, Dasu MR et al. Improved net protein balance, lean mass, and gene expression changes with oxandrolone treatment in the severely burned. Ann Surg. 2003; 237:801-11. [PubMed 12796576]
19. Grunfeld C, Kotler DP, Dobs A et al. Oxandrolone in the treatment of HIV-associated weight loss in men: a randomized, double-blind, placebo-controlled study. J Acquir Immune Defic Syndr. 2006; 41:304-14. [PubMed 16540931]
20. Kravetz JD, Lee C, Dieterich DT. Oxandrolone use in Crohn’s disease. Am J Gastroenterol. 1997; 92:2330-1. Letter [PubMed 9399787]
21. Dickerman RD, Joseph AM, Bennett MT. Corticosteroid-induced myopathy in spinal cord injury patients: a role for anticatabolic agents? Spinal Cord. 2006; 44:263-4. Letter
22. Shahidi NT. A review of the chemistry, biological action, and clinical applications of anabolic-androgenic steroids. Clin Ther. 2001; 23:1355-90. [PubMed 11589254]
23. Riggs BL, Jowsey J, Kelly PJ et al. Studies on pathogenesis and treatment in postmenopausal and senile osteoporosis. Clin Endocrinol Metab. 1973; 2:317-32. [PubMed 4373194]
24. Bristol-Myers Squibb. Coumadin (warfarin sodium) tablets crystalline and Coumadin (warfarin sodium) for injection prescribing information. Princeton, NJ; 2007 Aug.
25. Massé R, Bi H, Ayotte C et al. Studies on anabolic steroids II—Gas chromatographic/mass spectrometric characterization of oxandrolone urinary metabolites in man. Biomed Environ Mass Spectrom. 1989; 18:429-38.
26. Koller EA, Wei X, Johnson TE. Oxandrolone steroid use and impaired coagulation. Arch Intern Med. 2006; 166:125. Letter. [PubMed 16401821]
27. Bi H, Massé R. Studies on anabolic steroids—12. Epimerization and degradation of anabolic 17β-sulfate-17α-methyl steroids in human: qualitative and quantitative GC/MS analysis. J Steroid Biochem Molec Biol. 1992; 42:533-46. [PubMed 1616883]
28. Gonzalez FJ, Tukey RH. Drug metabolism. In: Brunton L, Lazo JS, Parker KL, eds. Goodman and Gilman’s the pharmacological basis of therapeutics. 11th ed. New York: McGraw-Hill; 2006:82.
29. August D, Teitelbaum D, Albina J et al. Guidelines for the use of parenteral and enteral nutrition in adult and pediatric patients. Section XI: Specific guidelines for disease—adults. JEPN. 2002; 26:61S-96SA.
30. ICN Pharmaceuticals. Android (methyltestosterone) capsules prescribing information. Costa Mesa, CA; 2001 Sep.
31. Upsher-Smith Laboratories. Androxy (fluoxymesterone) tablets prescribing information. Minneapolis, MN; 2006 May.
32. Savient Pharmaceuticals, East Brunswick, NJ: Personal communication
33. AHFS drug information 2008. McEvoy GK, ed. Corticosteroids general statement. Bethesda, MD: American Society of Health-System Pharmacists; 2008:3088.
34. Alaven Pharmaceutical. Anadrol (oxymetholone) prescribing information. Marietta, GA; 2006 Dec.
